Innovative Footwear Clinically Proven to Reduce Knee Pain and Improve Joint Function
Over 20 million people in the UK, have a Musculoskeletal (MSK) condition such as knee or back pain.
People are living longer with complex MSK conditions, increasing demand on MSK services.
MSK conditions are more common in areas of poverty and may affect some ethnic groups more than others, how patients access and experience care can also vary.
A standard treatment pathway for managing patients with knee osteoarthritis (OA) includes physiotherapy, weight loss, pain relief and walking aids.
Once patients experience joint symptoms (pain, stiffness) that have an impact on their quality of life or standard care treatment is no longer working, they should be considered for surgery.
AposHealth® Solution Intervention
Apos® is targeted for patients who would normally be referred for surgery and works on biomechanical and neuromuscular levels.
This is an innovative, non-invasive shoe that is personalised to treat the cause of a patient’s pain, by retraining how they walk to support better movement.
This National Institute for Health and Care Excellence (NICE) recommended device is clinically proven to relieve pain and improve function in the knees and lower back.
The image below shows how Apos® can be used with patients before surgery.
Two customised pods are attached to a tailored shoe device, which patients are required to wear for an hour a day, the pods are individually designed to meet a patient needs.
Neuromuscular retraining
The pods’ convexity creates micro-instability that increases proprioception and retrains the muscular system.
Biomechanical redistribution
Customised pod positioning reduces the forces acting on the patient’s painful knee, reducing pain and improving their gait.
Enquire Now About Apos®
Complete our two minute enquiry form and your regional Clinical Nurse Advisor will respond with further details.
Proposed Pathway Diagram
See our Downloads ▼ section to view a printable PDF version.
MedTech Funding Mandate
From April 2024 Apos® will be covered by NHS England’s MedTech Funding Mandate policy (MTFM). The MTFM aims to ensure patients and the NHS benefit from clinically effective and cost saving medical technologies faster and fairly.
Technologies covered by the MTFM are typically funded by commissioners from their existing allocations. This is deliverable as the technologies supported are NICE recommended and meet the criteria to save costs and resources and make a return on investment within three years.
NHS Supply Chain work alongside the Health Innovation Network (HINs) and APOSHealth® to clinically implement this product. To find out more information, please contact our Care Pathway Team through the enquiry form.
Links section
-
NHS England Best Practice Solutions - Musculoskeletal
Find more information on NHS England's website.
-
APOSHealth®
Further research on this product can be found here.
-
NICE Recommendations
View the NICE recommendation here.
-
MedTech Funding Mandate
View information about the MedTech Funding Mandate and the products available through our supply route.
-
Clinical Nurse Advisors
Our Regional Clinical Nurse Advisors can help to improve the link between procurement and clinicians.